ASHRAF ELSHAFEI: Open Payments
NPI 1083816755 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,718 in 61 payments from 10 companies in 2025. Trend: 2023 $1,225 · 2024 $1,308 · 2025 $1,718
Food & beverage: $1,597Education: $122
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $737 |
| Teva Pharmaceuticals USA, Inc. | 10 | $264 |
| E.R. Squibb & Sons, L.L.C. | 8 | $219 |
| Otsuka America Pharmaceutical, Inc. | 8 | $196 |
| Vanda Pharmaceuticals Inc. | 3 | $97 |
| Lundbeck LLC | 3 | $82 |
| ABBVIE INC. | 2 | $50 |
| Corium, LLC | 1 | $26 |
| Janssen Pharmaceuticals, Inc | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
Products named: CAPLYTA, COBENFY, UZEDY, ABILIFY MAINTENA, FANAPT, ABILIFY ASIMTUFII, REXULTI, VRAYLAR.
Industry payments across NY — which companies pay providers there.
